File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, randomized, placebo-controlled trial

TitleThe efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, randomized, placebo-controlled trial
Authors
KeywordsNimodipine
Acute ischemic stroke
Mild cognitive impairment
Cognitive decline
Prevention
Issue Date2019
PublisherPublished by Elsevier B.V. and Science China Press. The Journal's web site is located at http://www.sciencedirect.com/science/journal/20959273?sdc=1
Citation
Science Bulletin, 2019, v. 64 n. 2, p. 101-107 How to Cite?
AbstractNimodipine might be effective in subcortical vascular dementia (VaD). Its benefit in preventing further cognitive decline in patients with acute ischemic stroke (AIS) and vascular mild cognitive impairment (VaMCI) remains to be established. In this multicenter, double-blind trial, we randomly assigned 654 eligible patients to nimodipine 30 mg three times a day or placebo. The primary outcome was any cognitive decline defined by the changes on the Mini-Mental State Examination (ΔMMSE ≤ −3) or vascular AD assessment scale cognitive subscale (ΔADAS-cog ≥ 4) at 6 months. Secondary outcomes included any distribution shift of ΔADAS-cog, ΔMMSE or cognitive improvement defined by ΔADAS-cog ≤ −2, or ΔMMSE ≥ 0. The primary outcome in the nimodipine group and placebo group were similar for ΔMMSE ≤ −3 (4.18% and 7.22%, respectively, P = 0.15) and ΔADAS-cog ≥ 4 (8.36% and 8.93% respectively, P = 0.88). The distribution shift of ΔADAS-cog and ΔMMSE differed significantly between the two groups (P = 0.03 and P = 0.05 respectively). Cognitive improvement occurred in 55.4% in the nimodipine group and 43.6% in the placebo group measured by ΔADAS-cog ≤ −2 (Odds Ratio, 1.54; 95% confidence interval [CI] 1.10–2.14, P < 0.01) or 84.0% and 74.6% respectively by ΔMMSE ≥ 0 (Odds Ratio, 1.79; 95% CI 1.18–2.70, P < 0.01). Nimodipine was associated with better cognitive function in the memory domain. The adverse events rate was similar in two groups. This study is registered with ClinicalTrials.gov, NCT01220622. Nimodipine did not show benefit to prevent cognitive decline in AIS patients with VaMCI, but improved cognition moderately, especially measured in the memory domain.
Persistent Identifierhttp://hdl.handle.net/10722/279005
ISSN
2019 Impact Factor: 9.511
2015 SCImago Journal Rankings: 0.477

 

DC FieldValueLanguage
dc.contributor.authorZheng, H-
dc.contributor.authorWang, Y-
dc.contributor.authorWang, A-
dc.contributor.authorLi, H-
dc.contributor.authorWang, D-
dc.contributor.authorZhao, X-
dc.contributor.authorWang, P-
dc.contributor.authorShen, H-
dc.contributor.authorZuo, L-
dc.contributor.authorPan, Y-
dc.contributor.authorLi, Z-
dc.contributor.authorMeng, X-
dc.contributor.authorWang, X-
dc.contributor.authorShi, W-
dc.contributor.authorJu, Y-
dc.contributor.authorLiu, L-
dc.contributor.authorDong, K-
dc.contributor.authorWang, C-
dc.contributor.authorSui, R-
dc.contributor.authorXue, R-
dc.contributor.authorPan, X-
dc.contributor.authorNiu, X-
dc.contributor.authorLuo, B-
dc.contributor.authorSui, Y-
dc.contributor.authorWang, H-
dc.contributor.authorFeng, T-
dc.contributor.authorWang, Y-
dc.contributor.authorThe NICE trial group,-
dc.date.accessioned2019-10-21T02:17:52Z-
dc.date.available2019-10-21T02:17:52Z-
dc.date.issued2019-
dc.identifier.citationScience Bulletin, 2019, v. 64 n. 2, p. 101-107-
dc.identifier.issn2095-9273-
dc.identifier.urihttp://hdl.handle.net/10722/279005-
dc.description.abstractNimodipine might be effective in subcortical vascular dementia (VaD). Its benefit in preventing further cognitive decline in patients with acute ischemic stroke (AIS) and vascular mild cognitive impairment (VaMCI) remains to be established. In this multicenter, double-blind trial, we randomly assigned 654 eligible patients to nimodipine 30 mg three times a day or placebo. The primary outcome was any cognitive decline defined by the changes on the Mini-Mental State Examination (ΔMMSE ≤ −3) or vascular AD assessment scale cognitive subscale (ΔADAS-cog ≥ 4) at 6 months. Secondary outcomes included any distribution shift of ΔADAS-cog, ΔMMSE or cognitive improvement defined by ΔADAS-cog ≤ −2, or ΔMMSE ≥ 0. The primary outcome in the nimodipine group and placebo group were similar for ΔMMSE ≤ −3 (4.18% and 7.22%, respectively, P = 0.15) and ΔADAS-cog ≥ 4 (8.36% and 8.93% respectively, P = 0.88). The distribution shift of ΔADAS-cog and ΔMMSE differed significantly between the two groups (P = 0.03 and P = 0.05 respectively). Cognitive improvement occurred in 55.4% in the nimodipine group and 43.6% in the placebo group measured by ΔADAS-cog ≤ −2 (Odds Ratio, 1.54; 95% confidence interval [CI] 1.10–2.14, P < 0.01) or 84.0% and 74.6% respectively by ΔMMSE ≥ 0 (Odds Ratio, 1.79; 95% CI 1.18–2.70, P < 0.01). Nimodipine was associated with better cognitive function in the memory domain. The adverse events rate was similar in two groups. This study is registered with ClinicalTrials.gov, NCT01220622. Nimodipine did not show benefit to prevent cognitive decline in AIS patients with VaMCI, but improved cognition moderately, especially measured in the memory domain.-
dc.languageeng-
dc.publisherPublished by Elsevier B.V. and Science China Press. The Journal's web site is located at http://www.sciencedirect.com/science/journal/20959273?sdc=1-
dc.relation.ispartofScience Bulletin-
dc.subjectNimodipine-
dc.subjectAcute ischemic stroke-
dc.subjectMild cognitive impairment-
dc.subjectCognitive decline-
dc.subjectPrevention-
dc.titleThe efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment: a double-blind, randomized, placebo-controlled trial-
dc.typeArticle-
dc.identifier.emailShen, H: haipeng@hku.hk-
dc.identifier.authorityShen, H=rp02082-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.scib.2018.12.006-
dc.identifier.scopuseid_2-s2.0-85059699018-
dc.identifier.hkuros308047-
dc.identifier.volume64-
dc.identifier.issue2-
dc.identifier.spage101-
dc.identifier.epage107-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats